SpaceX's IPO Run May Already Be Over — and It Could Get a Lot Worse

SpaceX completed the largest U.S. IPO in history, raising $85.7 billion, and the stock finished its first week about 37% above the $135 offer price after peaking at $225.64 intraday. However, the $60 billion all-stock Anysphere acquisition, pending lockup expirations, and a possible $20 billion bridge-loan refinancing could create meaningful dilution and supply pressure. The article argues the near-term risk is less about business fundamentals and more about share count growth and stock overhang.

Analysis

The market is likely underestimating how quickly a great IPO can turn into a supply event. Once a stock becomes both a financing currency and a liquidity source for employees/early holders, price discovery shifts from narrative scarcity to mechanical distribution; that typically compresses multiple even if fundamentals remain intact. In this setup, the near-term winner is not the equity holder but the capital-markets complex around it: underwriters, bond investors, and any private competitors that can benefit from a temporarily distracted public market appetite.

The biggest second-order effect is competitive. If this company starts using stock to buy growth, it signals to rivals that equity can be an aggressive acquisition weapon, but only while the stock is richly valued. That can force other AI and space-adjacent names into a relative disadvantage if they must fund growth with cash or debt instead of paper; the market will likely start rewarding balance-sheet flexibility over pure growth optionality.

The more important risk window is the next 1-3 months, not the next 3-5 years. IPO lockup expiry, employee selling, and financing actions can overlap into a self-reinforcing overhang, especially if the stock loses momentum and early holders front-run distribution. The only clean reversal catalyst is evidence that incremental issuance is being absorbed by new fundamental buyers faster than supply expands; absent that, technical pressure can dominate even if the business outlook stays strong.

Consensus is probably over-fixated on the strategic logic of the acquisition and underweight the market microstructure. A stock can be ‘good’ and still be a poor long if the float, leverage, and acquisition currency dynamics create a persistent supply glut. The better contrarian framing is that the first post-IPO drawdown may be less about disappointment and more about the market repricing scarcity, with any dip buying most attractive only after the first large capital action clears.

Key Decisions for Investors

• Sell/short into strength on the newly listed stock over the next 2-6 weeks; use tight risk controls above recent post-IPO highs because the setup is dominated by supply expansion rather than valuation support.
• Buy downside via put spreads 1-3 months out on the newly listed name; structure for a 2-3x payoff if lockup/financing headlines trigger a 15-25% re-rating lower.
• Pair trade: long a cash-rich AI beneficiary with no near-term dilution risk vs short the newly listed acquirer; this isolates the market’s tolerance for dilution and acquisition-currency issuance.
• Avoid chasing other recent IPOs in the same window; if this deal marks a reopening of issuance, the first-order trade is likely a higher cost of capital for the whole cohort as investors demand a discount for float expansion.
• If bond issuance is announced at size, consider covering part of any short: refinancing with debt instead of equity may temporarily reduce immediate dilution, though it can increase leverage risk over 6-18 months.